This data compares favorably to the CRc of 54% with single agent gilteritinib in the ADMIRAL study; suggesting gilteritinib plus venetoclax might be better option for R/R FLT3-mutated AML, while longer follow-up with OS data is awaited [56]. This evidence concerns the gene FLT3 and acute myeloid leukemia.